| Background and PurposeMammary organ is a special mammalian organ of human and mammalian,and it is an important organ for female mammals to breed offspring.Breast cancer is a malignant tumor occurring in the epithelium of the breast.Breast cancer has become a major public health problem,present in our country the number of female breast cancer increases year by year,the global incidence of breast cancer also has been on the rise since the late 1970 s,the incidence of breast cancer usually increases with age,but the epidemiology investigation shows that our country breast cancer patients gradually younger.The latest statistics show that the number one female malignant tumor is breast cancer.With the increase of people’s health awareness,the progress of breast cancer screening and the advancement of medical imaging,the positive detection rate of breast cancer is increasing,but locally advanced breast cancer still accounts for a large proportion.Neoadjuvant chemotherapy(NAC)also known as preoperative chemotherapy,its advantage lies in the down-stage tumor,making the inoperable lesion suitable for surgery or meeting the patient’s milk-retaining needs.It can also determine the sensitivity of the lesion to chemotherapy drugs,and help guide effective postoperative adjuvant chemotherapy.It is now part of the treatment of locally advanced breast cancer(LABC).Breast cancer is a malignant tumor with high atypia at the molecular level.The same clinicopathological features may have different molecular biological behaviors.Current breast cancer treatment is based on molecular classification.According to the expression of biological factors estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor 2(HER-2)and Ki-67 in immunohistochemistry results,it is divided into Luminal type A and Luminal type B,HER-2 overexpression and Basal-like.The clinical features of four types of breast cancer are:Luminal A and Luminal B breast cancer account for 50%-70%of the total incidence.These two types of patients are not sensitive to chemotherapy,but the prognosis is better.The incidence of HER-2 overexpressing breast cancer accounts for15%to 20%of the total incidence.These patients are sensitive to neoadjuvant chemotherapy,but the prognosis is poor.The incidence of Basal-like breast cancer accounts for 10%to 15%of the total incidence.This type of classification is sensitive to neoadjuvant chemotherapy,but the prognosis is poor.Different types have different biological characteristics,and the therapeutic effects and clinical prognosis are also different.Accurate analysis of breast cancer molecular typing,better development of chemotherapy for patients,individualized treatment.Retrospective research method,selected 148 eligible breast cancer patients who were admitted to the Third Affiliated Hospital of Zhengzhou University from January 2016 to June 2018 as subjects.According to the classification of immunohistochemistry results,the sensitivity of different molecular breast cancers to neoadjuvant chemotherapy was explored,and the influencing factors and prognosis were determined.Materials and MethodsInvestigate 148 cases of breast cancer patients who met the conditions after diagnosis by air-core needle puncture in our hospital from January 2016 to June2018.Record clinical and pathological data of all eligible breast cancer patients,including age,menstrual status,tumor size,etc.To analyze the relationship between different types of breast cancer and clinicopathological features,and to evaluate the relationship between different types of breast cancer,clinicopathological features,curative effect and prognosis.The data were analyzed by SPSS 17.0 software.The molecular analysis of breast cancer,clinical pathological data and clinical and pathological efficacy were analyzed byχ~2test.Counting indicators take data and percentage representation.p<0.05 indicated that the difference was statistically significant.Results1.There were 14 cases of Luminal type A,46 cases of Luminal type B,36 cases of Her-2 overexpression type and 52 cases of Basal-like type.The clinical effective rates were 35.7%,43.5%,66.7%and 73.1%.The p CR rate was 7.1.%,8.7%,22.2%,and 30.8%.The HER-2 overexpression and Basal-like type had higher clinical remission rate and p CR rate than the Luminal type(p=0.026),and the difference was statistically significant(p<0.05).2.There were no significant differences in the general characteristics of age,menstrual status and tumor size between the four types of breast cancer patients(p>0.05).The difference in body mass index was statistically significant(p<0.05).Conclusions1.HER-2 overexpression and Basal-like type are more sensitive to neoadjuvant chemotherapy than Luminal type,which can better obtain clinical remission rate and p CR rate.2.Breast cancer classification is important for predicting efficacy and prognosis. |
PDF Full Text Request